Capsule endoscopy (CE), introduced in 2000 and FDA-approved in 2001, remains a valuable tool for diagnosing gastrointestinal (GI) lesions, particularly in areas inaccessible to traditional endoscopy. While CE offers non-invasive imaging and improves detection of small bowel diseases and obscure GI bleeding, its widespread use is hindered by limitations such as lack of therapeutic capabilities, inability to obtain biopsies, reliance on peristalsis for movement, and time-consuming image interpretation.
Trending
- Patients now shop for doctors like consumers, and the bar just got higher (Medical Economics)
- AI in GI cancer care: From recognition to clinical value (ESMO)
- Could the Gut Microbiome Improve Colorectal Cancer Screening? (Technology Networks)
- DDW Expert Picks: Endoscopists’ Peripheral Gaze, Antibiotics for Cholangitis, and More (GI & Endoscopy News)
- The loopholes PE built to buy physicians are starting to crack (Becker’s Healthcare)
- Barrett Esophagus May Strike Decades Before Official Diagnosis (Medscape)
- A blood-based test for detection of advanced adenomas and colorectal cancer (DENEB): a multicentre diagnostic accuracy study (The Lancet Gastroenterology & Hepatology)
- AI can analyze your poop. Should it? (Business Insider)
